Company

About Cosmo Pharmaceuticals

Cosmo is an emerging fully-integrated speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn’s Disease, as well as for colon infections.

Cosmo's lead product Lialda™, the first product based on MultiMatrix Technology ("MMX™"), was launched into the US market by Shire Pharmaceuticals plc on 19 March 2007. Another product, Zacol NMX™, is marketed in Italy.  In addition the company has four drug candidates: Budesonide MMX™ which is in phase III, Rifamycin MMX™ which is in clinical phase II/III and LMW Heparin MMX™ in phase II . These products will address unmet needs in the IBD market. This market is expected to grow, primarily because old and less effective products will be replaced by more effective ones. CB-03-01, the first new chemical entity the Company is developing completed the first phase I clinical trials.

Cosmo’s proprietary MMX™ technology is at the core of the company’s product pipeline and was developed from its expertise in formulating and manufacturing gastro-intestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy.